Proteomics analysis revealed that miR-23a-3p inhibitors could prevent ACSL4 overexpression and reduce sorafenib-induced lipid peroxidation and cellular iron accumulation, suggesting that miR-23a-3p can affect ferroptosis by regulating ACSL4 to affect sorafenib resistance in hepatocellular carcinoma (23). Here, ACSL4 is linked to hepatocellular carcinoma.